<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "chimeric antigen receptor" OR "CAR T" OR "CAR-"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Impaired tumor death receptor signaling drives resistance to CAR T cell therapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/627562v1">Link</a></p><p><b>Date:</b> 2019-05-05</p><p><b>Authors:</b> Nathan Singh ... Marco Ruella</p><p><b>Downloads:</b> 1273</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Cellular immunotherapy using T cells engineered to express chimeric antigen receptors targeting CD19 (CART19) leads to long-term remission in patients with B-cell malignancies.  Unfortunately, a significant fraction of patients demonstrate primary resistance to CART19 or experience relapse after achieving remission.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Evaluation of a very brief pedometer-based physical activity intervention delivered in NHS Health Checks in England: The VBI randomised controlled trial.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32142507">Link</a></p><p><b>Date:</b> 03/06/2020</p><p><b>Authors:</b> Wendy Hardeman ...  None None</p><p><b>Journal:</b> PLoS Med.</p><p><b>IF (7 or above):</b> 9.39</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: The majority of people do not achieve recommended levels of physical activity.  There is a need for effective, scalable interventions to promote activity.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Functional effects of chimeric antigen receptor co-receptor signaling domains in human Tregs</h4><p><a href="https://www.biorxiv.org/content/10.1101/749721v1">Link</a></p><p><b>Date:</b> 2019-08-29</p><p><b>Authors:</b> Nicholas A.J. Dawson ... Megan K Levings</p><p><b>Downloads:</b> 806</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Antigen-specific regulatory T cells (Tregs) engineered with chimeric antigen receptor (CARs) are a potent immunosuppressive cellular therapy in multiple disease models.  To date the majority of CAR Treg studies employed second generation CARs, encoding a CD28 or 4-1BB co-receptor signaling domain and CD3zeta, but it was not known if this CAR design was optimal for Tregs.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Witnessing, Remembering, and Testifying: Why the Past Is Special for Human Beings.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31961781">Link</a></p><p><b>Date:</b> 01/21/2020</p><p><b>Authors:</b> Johannes B Mahr ...  Gergely Csibra</p><p><b>Journal:</b> Perspect Psychol Sci</p><p><b>IF (7 or above):</b> 8.40</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The past is undeniably special for human beings.  To a large extent, both individuals and collectives define themselves through history.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting</h4><p><a href="https://www.biorxiv.org/content/10.1101/696401v2">Link</a></p><p><b>Date:</b> 2019-07-09</p><p><b>Authors:</b> Kyle E. Landgraf ... Kaman Chan Kim</p><p><b>Downloads:</b> 723</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> We have developed a chimeric antigen receptor (CAR) platform that functions as a modular system to address limitations of current CAR therapies.  An inert form of the NKG2D extracellular domain (iNKG2D) was used as the ectodomain of the CAR to generate convertibleCAR-T cells.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Genetic dissection of the gene coexpression network underlying photosynthesis in Populus.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31584236">Link</a></p><p><b>Date:</b> 10/04/2019</p><p><b>Authors:</b> Liang Xiao ...  Deqiang Zhang</p><p><b>Journal:</b> Plant Biotechnol. J.</p><p><b>IF (7 or above):</b> 7.11</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Photosynthesis is a key reaction that ultimately generates the carbohydrates needed to form woody tissues in trees.  However, the genetic regulatory network of protein-encoding genes (PEGs) and regulatory noncoding RNAs (ncRNAs), including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), underl ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/642934v1">Link</a></p><p><b>Date:</b> 2019-05-20</p><p><b>Authors:</b> Mahboubeh Yazdanifar ... Pinku Mukherjee</p><p><b>Downloads:</b> 326</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptor engineered T cells (CAR T cells) have shown remarkable success in treating hematologic cancers.  However, this efficacy has yet to translate to treatment in solid tumors.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999-2018.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32125357">Link</a></p><p><b>Date:</b> 03/03/2020</p><p><b>Authors:</b> Olivier J Wouters</p><p><b>Journal:</b> JAMA Intern Med</p><p><b>IF (7 or above):</b> 14.57</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Importance: Government efforts to lower drug costs and other legislative and regulatory initiatives may be counteracted by campaign donors and lobbyists in the pharmaceutical and health product industry. 
Objective: To review how much money the pharmaceutical and health product industry spent on cam ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Chlorotoxin Redirects Chimeric Antigen Receptor T Cells for Specific and Effective Targeting of Glioblastoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.24.918888v1">Link</a></p><p><b>Date:</b> 2020-01-25</p><p><b>Authors:</b> Dongrui Wang ... Christine E. Brown</p><p><b>Downloads:</b> 194</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> While chimeric antigen receptor (CAR) T cells have demonstrated antitumor activity against glioblastoma (GBM), tumor heterogeneity remains a critical challenge.  To more effectively target heterogeneous GBMs, we report the development of a novel peptide-based CAR exploiting the GBM-binding potential of chlorotoxin (CLTX).</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Rational Design of Mechanism-Based Inhibitors and Activity-Based Probes for the Identification of Retaining α-l-Arabinofuranosidases.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32053363">Link</a></p><p><b>Date:</b> 02/13/2020</p><p><b>Authors:</b> Nicholas G S McGregor ...  Gideon J Davies</p><p><b>Journal:</b> J. Am. Chem. Soc.</p><p><b>IF (7 or above):</b> 14.50</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Identifying and characterizing the enzymes responsible for an observed activity within a complex eukaryotic catabolic system remains one of the most significant challenges in the study of biomass-degrading systems.  The debranching of both complex hemicellulosic and pectinaceous polysaccharides requ ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.30.926535v1">Link</a></p><p><b>Date:</b> 2020-01-30</p><p><b>Authors:</b> Yvette Robbins ... Clint T. Allen</p><p><b>Downloads:</b> 187</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy.  This approach may still be limited by the presence of immunosuppressive myeloid populations.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Perfect adaptation of CD8+ T cell responses to constant antigen input over a wide range of affinity is overcome by costimulation</h4><p><a href="https://www.biorxiv.org/content/10.1101/535385v2">Link</a></p><p><b>Date:</b> 2019-01-30</p><p><b>Authors:</b> Nicola Trendel ... Omer Dushek</p><p><b>Downloads:</b> 704</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Maintaining and limiting T cell responses to constant antigen stimulation is critical to control pathogens and maintain self-tolerance, respectively.  Antigen recognition by T cell receptors (TCRs) induces signalling that activates T cells to produce cytokines and also leads to the downregulation of surface TCRs.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio</h4><p><a href="https://www.biorxiv.org/content/10.1101/646760v1">Link</a></p><p><b>Date:</b> 2019-05-23</p><p><b>Authors:</b> Nathan J. Dwarshuis ... Krishnendu Roy</p><p><b>Downloads:</b> 633</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Adoptive cell therapies (ACT) using chimeric antigen receptor (CAR) T cells have shown promise in treating cancer, but manufacturing large numbers of high quality cells remains challenging.  Critically, current T cell expansion technologies only partially recapitulate the in vivo microenvironment found in the human lymph nodes.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Identification of human CD4+ T cell populations with distinct antitumor activity</h4><p><a href="https://www.biorxiv.org/content/10.1101/2019.12.31.891317v1">Link</a></p><p><b>Date:</b> 2020-01-02</p><p><b>Authors:</b> Michelle H. Nelson ... Chrystal Paulos</p><p><b>Downloads:</b> 438</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> How naturally arising human CD4+ T helper subsets impact tumor immunity is unknown.  We reported that human CD4+CD26high T cells elicit potent immunity against solid tumor malignancies.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Three-Compartment Model of CAR T-cell Immunotherapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/779793v1">Link</a></p><p><b>Date:</b> 2019-09-24</p><p><b>Authors:</b> Brendon de Jesus Rodrigues ... Regina C. Almeida</p><p><b>Downloads:</b> 376</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunotherapy has gained great momentum with CAR T (chimeric antigen receptor) cellular therapy, in which the patients T lymphocytes are genetically manipulated to recognize tumor-specific antigens to increase elimination efficiency.  Although recently approved by FDA to treat B cell malignancies, issues such as dose, administration protocol, toxicity, resistance to immunotherapy, among others, remain open and are the subject of intense research nowadays.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging</h4><p><a href="https://www.biorxiv.org/content/10.1101/789727v1">Link</a></p><p><b>Date:</b> 2019-10-01</p><p><b>Authors:</b> Suk Hyun Lee ... Jin-Sook Ryu</p><p><b>Downloads:</b> 114</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Introduction: Chimeric antigen receptor (CAR) T-cells have been developed recently, producing impressive outcomes in patients with hematologic malignancies.  However, there is no standardized method for cell trafficking and in vivo CAR T-cell monitoring.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.17.909895v1">Link</a></p><p><b>Date:</b> 2020-01-17</p><p><b>Authors:</b> Jason Lohmueller ... Olivera J. Finn</p><p><b>Downloads:</b> 337</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.  To expand the targeting capabilities of these receptors, we have developed switchable adaptor receptor systems for which receptor specificity can be directed post-translationally via covalent attachment of a co-administered antibody.</p></div></td></div><td></td></tr></table></div><hr></div></body></html>